Medline (NASDAQ:MDLN) Raised to Strong-Buy at The Goldman Sachs Group

Medline (NASDAQ:MDLN) was upgraded by stock analysts at The Goldman Sachs Group to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Several other equities research analysts have also commented on MDLN. Stifel Nicolaus began coverage on Medline in a research note on Monday. They set a “buy” rating and a $46.00 price target for the company. BNP Paribas assumed coverage on Medline in a report on Monday. They set a “neutral” rating and a $38.00 target price for the company. Morgan Stanley began coverage on shares of Medline in a report on Sunday. They issued an “overweight” rating and a $48.00 price target on the stock. Robert W. Baird initiated coverage on shares of Medline in a research note on Monday. They set an “outperform” rating and a $48.00 price objective for the company. Finally, BNP Paribas Exane started coverage on shares of Medline in a research report on Monday. They issued a “neutral” rating and a $38.00 price objective for the company. Eight investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $46.70.

Medline Price Performance

MDLN stock opened at $42.72 on Monday. Medline has a 52 week low of $34.89 and a 52 week high of $45.50.

Insider Transactions at Medline

In other news, Director Charles N. Mills bought 2,579,310 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was acquired at an average cost of $29.00 per share, for a total transaction of $74,799,990.00. Following the completion of the purchase, the director owned 2,441,379 shares of the company’s stock, valued at $70,799,991. This trade represents a -1,870.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the sale, the insider directly owned 4,806,160 shares of the company’s stock, valued at approximately $136,350,759.20. The trade was a 55.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Numerous analysts initiated buy/overweight ratings (Barclays, Jefferies, Bank of America, JPMorgan, Wolfe, Mizuho, TD Cowen, Stifel, Piper Sandler, Bernstein, J.P. Morgan, William Blair, Robert W. Baird, Truist). Several targets sit in the $46–$52 range, implying notable upside and helping fuel buying interest. Medline Stock Surges on Post‑IPO Buy Notes
• Positive Sentiment: Jefferies highlighted Medline’s $25 billion supply‑chain scale and gave a “buy” in its coverage debut — a validation of the company’s scale and margin expansion thesis that investors favor. Jefferies Coverage
• Positive Sentiment: Benzinga and other outlets note Medline raised ~$7 billion in its IPO and is being praised for a “prime vendor” model, branded mix shift and margin expansion potential — fundamental reasons analysts cite for buy ratings. Analysts Say Medline Has The Secret Sauce
• Neutral Sentiment: Valuation checks and commentary: several writeups assess MDLN near discounted cash‑flow estimates or “fairly priced” after the recent stability — these limit runaway upside and suggest gains are tied to multiple expansion as much as earnings. Valuation Check
• Neutral Sentiment: Short interest report in the period shows effectively zero/ambiguous data (odd reporting numbers). No clear short‑squeeze signal — treat short‑interest data as non‑contributory for now.
• Negative Sentiment: Some shops initiated neutral/hold ratings with lower targets (BNP Paribas $38 target, Deutsche Bank $40, Wells Fargo $42, Rothschild $42). Those lower targets cap consensus upside and could pressure the stock if follow‑through selling emerges.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.